person · Reporting owner
Kelly-Gemmell Dorothy Elizabeth
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viking Therapeutics, Inc.VKTX · Entity 4067 | Director | August 01, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viking Therapeutics, Inc.
Report date August 01, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 6,333 |
Reported balance
After 2026-08-01 transaction · row 1
1 source rowRow 1 · 2026-08-01 · Grant · Acquired 6,333 · Balance 6,333 F1: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.74 · Expires 2036-08-01 | Direct | 40,800 |
Reported balance
After 2026-08-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-01 · Grant · Acquired 40,800 · Balance 40,800 F2: One-third of the shares subject to the option will vest on each anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award.
F2: One-third of the shares subject to the option will vest on each anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2026 Filed Aug 7, 2026 20:34 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 40,800 | $0.00 Strike: $31.74 | $0.00 |
DisclosureSEC source: 0002144542-26-000004 · ownership.xml · derivative · entry 2 Kelly-Gemmell Dorothy Elizabeth · CIK 0002144542 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,800 Underlying: Common Stock · 40,800 shares Expires 2036-08-01 F2 · derivative.exercise_date: One-third of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| August 01, 2026 Filed Aug 7, 2026 20:34 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 6,333 | $0.00 | $0.00 |
DisclosureSEC source: 0002144542-26-000004 · ownership.xml · nonDerivative · entry 1 Kelly-Gemmell Dorothy Elizabeth · CIK 0002144542 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,333 F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.